[MAYBANK] QoQ TTM Result on 30-Jun-2016 [#2]

Announcement Date
25-Aug-2016
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2016
Quarter
30-Jun-2016 [#2]
Profit Trend
QoQ- -6.47%
YoY- -10.06%
View:
Show?
TTM Result
31/03/17 31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 CAGR
Revenue 44,753,568 44,657,902 44,464,550 44,559,857 42,554,416 40,556,371 39,165,809 9.28%
PBT 9,162,175 8,844,450 8,347,548 8,274,386 8,840,880 9,151,548 9,206,431 -0.32%
Tax -1,904,080 -1,880,558 -2,106,398 -1,971,165 -2,115,600 -2,165,160 -1,937,022 -1.13%
NP 7,258,095 6,963,892 6,241,150 6,303,221 6,725,280 6,986,388 7,269,409 -0.10%
-
NP to SH 7,019,038 6,742,992 6,034,476 6,137,712 6,562,305 6,835,939 7,115,090 -0.90%
-
Tax Rate 20.78% 21.26% 25.23% 23.82% 23.93% 23.66% 21.04% -
Total Cost 37,495,473 37,694,010 38,223,400 38,256,636 35,829,136 33,569,983 31,896,400 11.37%
-
Net Worth 70,457,936 68,422,732 65,606,580 62,312,149 61,977,906 61,131,868 59,603,594 11.78%
Dividend
31/03/17 31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 CAGR
Div 5,225,070 5,225,070 4,869,452 4,869,452 5,170,805 5,170,805 5,340,380 -1.44%
Div Payout % 74.44% 77.49% 80.69% 79.34% 78.80% 75.64% 75.06% -
Equity
31/03/17 31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 CAGR
Net Worth 70,457,936 68,422,732 65,606,580 62,312,149 61,977,906 61,131,868 59,603,594 11.78%
NOSH 10,178,105 10,179,378 9,992,777 9,838,346 9,745,566 9,672,611 9,528,037 4.49%
Ratio Analysis
31/03/17 31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 CAGR
NP Margin 16.22% 15.59% 14.04% 14.15% 15.80% 17.23% 18.56% -
ROE 9.96% 9.85% 9.20% 9.85% 10.59% 11.18% 11.94% -
Per Share
31/03/17 31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 CAGR
RPS 439.70 438.71 444.97 452.92 436.65 419.29 411.06 4.58%
EPS 68.96 66.24 60.39 62.39 67.34 70.67 74.68 -5.16%
DPS 51.34 51.33 48.73 49.49 53.06 53.46 56.05 -5.67%
NAPS 6.9225 6.7217 6.5654 6.3336 6.3596 6.3201 6.2556 6.97%
Adjusted Per Share Value based on latest NOSH - 9,838,346
31/03/17 31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 CAGR
RPS 370.88 370.08 368.48 369.27 352.65 336.09 324.57 9.29%
EPS 58.17 55.88 50.01 50.86 54.38 56.65 58.96 -0.89%
DPS 43.30 43.30 40.35 40.35 42.85 42.85 44.26 -1.44%
NAPS 5.8389 5.6703 5.4369 5.1639 5.1362 5.0661 4.9394 11.78%
Price Multiplier on Financial Quarter End Date
31/03/17 31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 CAGR
Date 31/03/17 30/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 -
Price 8.92 8.20 7.50 8.14 9.02 8.40 8.56 -
P/RPS 2.03 1.87 1.69 1.80 2.07 2.00 2.08 -1.60%
P/EPS 12.93 12.38 12.42 13.05 13.40 11.89 11.46 8.37%
EY 7.73 8.08 8.05 7.66 7.47 8.41 8.72 -7.71%
DY 5.76 6.26 6.50 6.08 5.88 6.36 6.55 -8.20%
P/NAPS 1.29 1.22 1.14 1.29 1.42 1.33 1.37 -3.92%
Price Multiplier on Announcement Date
31/03/17 31/12/16 30/09/16 30/06/16 31/03/16 31/12/15 30/09/15 CAGR
Date 25/05/17 23/02/17 24/11/16 25/08/16 27/05/16 25/02/16 26/11/15 -
Price 9.39 8.40 7.70 7.90 8.27 8.64 8.48 -
P/RPS 2.14 1.91 1.73 1.74 1.89 2.06 2.06 2.57%
P/EPS 13.62 12.68 12.75 12.66 12.28 12.23 11.36 12.84%
EY 7.34 7.89 7.84 7.90 8.14 8.18 8.81 -11.44%
DY 5.47 6.11 6.33 6.27 6.42 6.19 6.61 -11.84%
P/NAPS 1.36 1.25 1.17 1.25 1.30 1.37 1.36 0.00%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment